nach oben

Erschienen in:

28.11.2017 | Case Report

Hematopoietic stem cell transplantation for pulmonary alveolar proteinosis associated with primary immunodeficiency disease

verfasst von: Mari Tanaka-Kubota, Koji Shinozaki, Satoshi Miyamoto, Masakatsu Yanagimachi, Tsubasa Okano, Noriko Mitsuiki, Masahiro Ueki, Masafumi Yamada, Kohsuke Imai, Masatoshi Takagi, Kazunaga Agematsu, Hirokazu Kanegane, Tomohiro Morio

Erschienen in: International Journal of Hematology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disorder that is characterized by the excessive accumulation of surfactant-like materials in the alveoli, leading to hypoxemic respiratory failure. We describe two Japanese infants with PAP associated with hypogammaglobulinemia and monocytopenia. These patients may have underlying primary immunodeficiency (PID) and were successfully treated with allogeneic hematopoietic stem cell transplantation (HSCT). This report indicates that allogeneic HSCT may provide a curative treatment for PAP associated with PID.

Nur mit Berechtigung zugänglich

Rosen SH, Casleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med. 1958;258:1123–42.CrossRefPubMed

Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527–37.CrossRefPubMed

Lin FC, Chang GD, Chern MS, Chen YC, Chang SC. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax. 2006;61:528–34.CrossRefPubMedPubMedCentral

Grunebaum E, Cutx E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol. 2012;129:1588–93.CrossRefPubMed

Raj D, Bhutia TD, Mathur S, Kabra SK, Lodha R. Pulmonary alveolar proteinosis secondary to Pneumocystis jiroveci infection in an infant with common variable immunodeficiency. Indian J Pediatr. 2014;81:929–31.CrossRefPubMed

Griese M, Zarbock R, Costabel U, Hildebrandt J, Theegarten D, Albert M, et al. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulm Med. 2015;15:87.CrossRefPubMedPubMedCentral

Dranoff G, Crawford AD, Sadelain M, Reem B, Rashid A, Bronson RT, et al. Involvement of granulocyte–macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264:713–6.CrossRefPubMed

Uchida K, Beck DC, Yamamato T, Berclaz PY, Abe S, Staudt MK, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med. 2007;356:567–79.CrossRefPubMed

Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010;182:1292–304.CrossRefPubMedPubMedCentral

10.

Spock A. Long-term survival of paediatric patients with pulmonary alveolar proteinosis treated with lung lavage. Eur Respir J. 2005;25:1127.CrossRefPubMed

11.

Hildebrandt J, Yalcin E, Bresser HG, Cinel G, Gappa M, Haghighi A, et al. Characterization of CSF2RA mutation related juvenile pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2014;9:171.CrossRefPubMedPubMedCentral

12.

Tabata S, Shimoji S, Murase K, Takiuchi Y, Inoue D, Kimura T, et al. Successful allogeneic bone marrow transplantation for myelodysplastic syndrome complicated by severe pulmonary alveolar proteinosis. Int J Hematol. 2009;90:407–12.CrossRefPubMed

13.

Fukuno K, Tomonari A, Tsukada N, Takahashi S, Ooi J, Konuma T, et al. Successful cord blood transplantation for myelodysplastic syndrome resulting in resolution of pulmonary alveolar proteinosis. Bone Marrow Transplant. 2006;38:581–2.CrossRefPubMed

14.

Happle C, Lachmann N, Škuljec J, Wetzke M, Ackermann M, Brennig S, et al. Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis. Sci Transl Med. 2014;6:250ra113.CrossRefPubMed

15.

Brasch F, Birzele J, Ochs M, Guttentag SH, Schoch OD, Boehler A, et al. Surfactant proteins in pulmonary alveolar proteinosis in adults. Eur Respir J. 2004;24:426–35.CrossRefPubMed

16.

Schoch OD, Schanz U, Koller M, Nakata K, Seymour JF, Russi EW, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-SCF. Thorax. 2002;57:277–80.CrossRefPubMedPubMedCentral

17.

Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenial alveolar proteinosis. N Engl J Med. 1993;328:406–10.CrossRefPubMed

18.

Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344:573–9.CrossRefPubMed

19.

Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004;350:1296–303.CrossRefPubMed

20.

Akimoto T, Cho K, Hayasaka I, Morioka K, Kaneshi Y, Furuta I, et al. Hereditary interstitial lung disease manifested by early childhood in Japan. Pediatr Res. 2014;76:453–8.CrossRefPubMed

21.

Dirksen U, Nishinakamura R, Gronexk P, Hattenhorst U, Nogee L, Murray R, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Investig. 1997;100:2211–7.CrossRefPubMedPubMedCentral

22.

Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008;205:2703–10.CrossRefPubMedPubMedCentral

23.

Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. Curr Opin Allergy Clin Immunol. 2015;15:104–9.CrossRefPubMedPubMedCentral

24.

Nishinakamura R, Wiler R, Dirksen U, Morikawa Y, Arai K, Miyajima A, et al. The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplantation. J Exp Med. 1996;183:2657–62.CrossRefPubMed

25.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, et al. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet J Rare Dis. 2016;11:115.CrossRefPubMedPubMedCentral

Titel: Hematopoietic stem cell transplantation for pulmonary alveolar proteinosis associated with primary immunodeficiency disease
verfasst von: Mari Tanaka-Kubota
Koji Shinozaki
Satoshi Miyamoto
Masakatsu Yanagimachi
Tsubasa Okano
Noriko Mitsuiki
Masahiro Ueki
Masafumi Yamada
Kohsuke Imai
Masatoshi Takagi
Kazunaga Agematsu
Hirokazu Kanegane
Tomohiro Morio
Publikationsdatum: 28.11.2017
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2018
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-017-2375-1

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Hematopoietic stem cell transplantation for pulmonary alveolar proteinosis associated with primary immunodeficiency disease

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Outcomes of strategic alternative donor selection or suspending donor search based on Japan Marrow Donor Program coordination status

ETV6–ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia

Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum

Hematopoietic stem cell transplantation for acute myeloid leukemia

Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302)

Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie